

# Naoki Suzuki

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1859503/publications.pdf>

Version: 2024-02-01

100  
papers

8,509  
citations

159585  
30  
h-index

46799  
89  
g-index

115  
all docs

115  
docs citations

115  
times ranked

18442  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetics of amyotrophic lateral sclerosis: seeking therapeutic targets in the era of gene therapy. <i>Journal of Human Genetics</i> , 2023, 68, 131-152.	2.3	39
2	Feeder-supported in vitro exercise model using human satellite cells from patients with sporadic inclusion body myositis. <i>Scientific Reports</i> , 2022, 12, 1082.	3.3	5
3	Long-term outcomes after surgery to prevent aspiration for patients with amyotrophic lateral sclerosis. <i>BMC Neurology</i> , 2022, 22, 94.	1.8	9
4	Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis. <i>Neurology</i> , 2021, 96, e1595-e1607.	1.1	25
5	A novel deletion in the C-terminal region of HSPB8 in a family with rimmed vacuolar myopathy. <i>Journal of Human Genetics</i> , 2021, 66, 965-972.	2.3	6
6	Reduced PHOX2B stability causes axonal growth impairment in motor neurons with TARDBP mutations. <i>Stem Cell Reports</i> , 2021, 16, 1527-1541.	4.8	10
7	A rare case of sporadic inclusion body myositis and rheumatoid arthritis exhibiting ectopic lymphoid follicle-like structures: a case report and literature review. <i>Neuromuscular Disorders</i> , 2021, 31, 870-876.	0.6	3
8	Puromycinâ€sensitive aminopeptidase is required for C2C12 myoblast proliferation and differentiation. <i>Journal of Cellular Physiology</i> , 2021, 236, 5293-5305.	4.1	9
9	A multi-ethnic meta-analysis identifies novel genes, including ACSL5, associated with amyotrophic lateral sclerosis. <i>Communications Biology</i> , 2020, 3, 526.	4.4	49
10	Inducible Rpt3, a Proteasome Component, Knockout in Adult Skeletal Muscle Results in Muscle Atrophy. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 859.	3.7	8
11	siRNA knockdown of alanine aminopeptidase impairs myoblast proliferation and differentiation. <i>Experimental Cell Research</i> , 2020, 397, 112337.	2.6	3
12	Generation of an ALS human iPSC line KEIOi001-A from peripheral blood of a Charcot disease-affected patient carrying TARDBP p.N345K heterozygous SNP mutation. <i>Stem Cell Research</i> , 2020, 47, 101896.	0.7	5
13	Hybrid Assistive LimbÂ® for sporadic inclusion body myositis: A case series. <i>Journal of Clinical Neuroscience</i> , 2020, 81, 92-94.	1.5	7
14	A case of inflammatory myopathy with antiâ€PM/Scl antibodies myopathologically presenting as polymyositis with mitochondrial pathology. <i>Neurology and Clinical Neuroscience</i> , 2020, 8, 335-339.	0.4	0
15	An Amyotrophic Lateral Sclerosis-Associated Mutant of C21ORF2 Is Stabilized by NEK1-Mediated Hyperphosphorylation and the Inability to Bind FBXO3. <i>IScience</i> , 2020, 23, 101491.	4.1	19
16	Aberrant interaction between FUS and SFPQ in neurons in a wide range of FTLDSpectrum diseases. <i>Brain</i> , 2020, 143, 2398-2405.	7.6	23
17	The ubiquitinâ€proteasome system in regulation of the skeletal muscle homeostasis and atrophy: from basic science to disorders. <i>Journal of Physiological Sciences</i> , 2020, 70, 40.	2.1	70
18	The genetic profile of dysferlinopathy in a cohort of 209 cases: Genotypeâ€phenotype relationship and a hotspot on the inner DysF domain. <i>Human Mutation</i> , 2020, 41, 1540-1554.	2.5	27

#	ARTICLE	IF	CITATIONS
19	Omics Approach to Axonal Dysfunction of Motor Neurons in Amyotrophic Lateral Sclerosis (ALS). <i>Frontiers in Neuroscience</i> , 2020, 14, 194.	2.8	42
20	AMPK Complex Activation Promotes Sarcolemmal Repair in Dysferlinopathy. <i>Molecular Therapy</i> , 2020, 28, 1133-1153.	8.2	9
21	Prognosis of amyotrophic lateral sclerosis patients undergoing tracheostomy invasive ventilation therapy in Japan. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 285-290.	1.9	30
22	Mitochondrial dysfunction underlying sporadic inclusion body myositis is ameliorated by the mitochondrial homing drug MA-5. <i>PLoS ONE</i> , 2020, 15, e0231064.	2.5	15
23	Inhibition of leucine aminopeptidase affects myocyte proliferation and differentiation. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.5	0
24	Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. <i>Lancet Neurology</i> , The, 2019, 18, 834-844.	10.2	91
25	In vitro exercise model using contractile human and mouse hybrid myotubes. <i>Scientific Reports</i> , 2019, 9, 11914.	3.3	25
26	The updated retrospective questionnaire study of sporadic inclusion body myositis in Japan. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 155.	2.7	12
27	Aberrant axon branching via Fos-B dysregulation in FUS-ALS motor neurons. <i>EBioMedicine</i> , 2019, 45, 362-378.	6.1	49
28	Pathogenic mutations in the ALS gene CCNF cause cytoplasmic mislocalization of Cyclin F and elevated VCP ATPase activity. <i>Human Molecular Genetics</i> , 2019, 28, 3486-3497.	2.9	24
29	A juvenile sporadic amyotrophic lateral sclerosis case with P525L mutation in the FUS gene: A rare co-occurrence of autism spectrum disorder and tremor. <i>Journal of the Neurological Sciences</i> , 2019, 398, 67-68.	0.6	18
30	p.N345K mutation in <i>TARDBP</i> in a patient with familial amyotrophic lateral sclerosis: An autopsy case. <i>Neuropathology</i> , 2019, 39, 286-293.	1.2	8
31	Interstitial pneumonia and other adverse events in riluzole-administered amyotrophic lateral sclerosis patients: a retrospective observational study. <i>BMC Neurology</i> , 2019, 19, 72.	1.8	14
32	FDG-PET detects extensive calcinosis cutis in anti-NXP2 antibody-positive dermatomyositis. <i>Rheumatology</i> , 2019, 58, 1888-1888.	1.9	3
33	Extranodal NK/T-cell Lymphoma Mimicking Granulomatous Myositis. <i>Internal Medicine</i> , 2019, 58, 277-282.	0.7	3
34	A novel homozygous mutation of the TFG gene in a patient with early onset spastic paraplegia and later onset sensorimotor polyneuropathy. <i>Journal of Human Genetics</i> , 2019, 64, 171-176.	2.3	4
35	Aberrant astrocytic expression of chondroitin sulfate proteoglycan receptors in a rat model of amyotrophic lateral sclerosis. <i>Journal of Neuroscience Research</i> , 2018, 96, 222-233.	2.9	21
36	The Ubiquitin-Proteasome System Is Indispensable for the Maintenance of Muscle Stem Cells. <i>Stem Cell Reports</i> , 2018, 11, 1523-1538.	4.8	54

#	ARTICLE	IF	CITATIONS
37	Phase I clinical trial results of aceneuramic acid for GNE myopathy in Japan. Translational Medicine Communications, 2018, 3, .	1.4	5
38	Antagonizing bone morphogenetic protein 4 attenuates disease progression in a rat model of amyotrophic lateral sclerosis. Experimental Neurology, 2018, 307, 164-179.	4.1	13
39	TARDBP p.G376D mutation, found in rapid progressive familial ALS, induces mislocalization of TDP-43. ENeurologicalSci, 2018, 11, 20-22.	1.3	17
40	Comprehensive targeted next-generation sequencing in Japanese familial amyotrophic lateral sclerosis. Neurobiology of Aging, 2017, 53, 194.e1-194.e8.	3.1	47
41	Pathomechanisms of anti“cytosolic 5â€²â€³nucleotidase 1<sc>A</sc> autoantibodies in sporadic inclusion body myositis. Annals of Neurology, 2017, 81, 512-525.	5.3	61
42	Five-year history of dysphagia as a sole initial symptom in inclusion body myositis. Journal of the Neurological Sciences, 2017, 381, 325-327.	0.6	13
43	Role of the Ubiquitin-Proteasome Pathway in Skeletal Muscle. , 2017, , 37-54.		0
44	Sporadic Inclusion Body Myositis Manifesting as Isolated Muscle Weakness of the Finger Flexors Three Years after Disease Onset. Internal Medicine, 2016, 55, 3521-3524.	0.7	3
45	Genotype“phenotype relationships in familial amyotrophic lateral sclerosis with <i>FUS/TLS</i> mutations in Japan. Muscle and Nerve, 2016, 54, 398-404.	2.2	16
46	Prominent sensory involvement in a case of familial amyotrophic lateral sclerosis carrying the L8V SOD1 mutation. Clinical Neurology and Neurosurgery, 2016, 150, 194-196.	1.4	6
47	Loss-of-function mutations in the <i>C9ORF72</i> mouse ortholog cause fatal autoimmune disease. Science Translational Medicine, 2016, 8, 347ra93.	12.4	217
48	Monitoring peripheral nerve degeneration in ALS by label-free stimulated Raman scattering imaging. Nature Communications, 2016, 7, 13283.	12.8	82
49	Multicenter questionnaire survey for sporadic inclusion body myositis in Japan. Orphanet Journal of Rare Diseases, 2016, 11, 146.	2.7	9
50	Deficient RNA-editing enzyme ADAR2 in an amyotrophic lateral sclerosis patient with a FUSP525L mutation. Journal of Clinical Neuroscience, 2016, 32, 128-129.	1.5	32
51	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
52	Establishment of InÂVitro FUS-Associated Familial Amyotrophic Lateral Sclerosis Model Using Human Induced Pluripotent Stem Cells. Stem Cell Reports, 2016, 6, 496-510.	4.8	74
53	<i>SLC52A3</i>, A Brown“Vialletto“van Laere syndrome candidate gene is essential for mouse development, but dispensable for motor neuron differentiation. Human Molecular Genetics, 2016, 25, 1814-1823.	2.9	12
54	Corticotropin-Releasing Hormone Receptor 2 Gene Variants in Irritable Bowel Syndrome. PLoS ONE, 2016, 11, e0147817.	2.5	21

#	ARTICLE	IF	CITATIONS
55	Associations between Single-Nucleotide Polymorphisms in Corticotropin-Releasing Hormone-Related Genes and Irritable Bowel Syndrome. PLoS ONE, 2016, 11, e0149322.	2.5	11
56	Isolated inclusion body myopathy caused by a multisystem proteinopathyâ€“linked <i>hnRNPA1</i> mutation. Neurology: Genetics, 2015, 1, e23.	1.9	34
57	Nonâ€“paraneoplastic Lambertâ€“Eaton myasthenic syndrome presenting dropped head and respiratory failure with normoreflexia. Neurology and Clinical Neuroscience, 2015, 3, 188-189.	0.4	1
58	Genetic profile for suspected dysferlinopathy identified by targeted next-generation sequencing. Neurology: Genetics, 2015, 1, e36.	1.9	22
59	Proteasome dysfunction induces muscle growth defects and protein aggregation. Journal of Cell Science, 2014, 127, 5204-17.	2.0	56
60	GNE myopathy associated with congenital thrombocytopenia: A report of two siblings. Neuromuscular Disorders, 2014, 24, 1068-1072.	0.6	49
61	Genetic validation of a therapeutic target in a mouse model of ALS. Science Translational Medicine, 2014, 6, 248ra104.	12.4	27
62	An Autopsy Case Involving a 12-year History of Amyotrophic Lateral Sclerosis with CIDP-like Polyneuropathy. Internal Medicine, 2014, 53, 1371-1375.	0.7	3
63	Proteasome Dysfunction Induces Muscle Growth Defects And Protein Aggregation. Medicine and Science in Sports and Exercise, 2014, 46, 352.	0.4	1
64	The mouse C9ORF72 ortholog is enriched in neurons known to degenerate in ALS and FTD. Nature Neuroscience, 2013, 16, 1725-1727.	14.8	67
65	Hereditary neuropathy with liability to pressure palsy emerging after hypothyroidism. Neurology and Clinical Neuroscience, 2013, 1, 160-161.	0.4	5
66	Exome sequencing identifies a novel TTN mutation in a family with hereditary myopathy with early respiratory failure. Journal of Human Genetics, 2013, 58, 259-266.	2.3	33
67	Clinical features and a mutation with late onset of limb girdle muscular dystrophy 2B. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 433-440.	1.9	52
68	Inflammatory demyelinating polyneuropathy with nephrotic syndrome: Report of a case and review of the literature. Clinical and Experimental Neuroimmunology, 2013, 4, 79-88.	1.0	0
69	Two Cases of Elderly-Onset Hereditary Neuropathy with Liability to Pressure Palsy Manifesting Bilateral Peroneal Nerve Palsies. Case Reports in Neurology, 2012, 4, 149-155.	0.7	7
70	FUS/TLS-immunoreactive Neuronal and Glial Cell Inclusions Increase With Disease Duration in Familial Amyotrophic Lateral Sclerosis With an R521C <i>FUS/TLS</i> Mutation. Journal of Neuropathology and Experimental Neurology, 2012, 71, 779-788.	1.7	36
71	Lower motor neuron disease caused by a novel FUS/TLS gene frameshift mutation. Journal of Neurology, 2012, 259, 2237-2239.	3.6	12
72	Continuous administration of poloxamer 188 reduces overload-induced muscular atrophy in dysferlin-deficient SJL mice. Neuroscience Research, 2012, 72, 181-186.	1.9	20

#	ARTICLE	IF	CITATIONS
73	Heterozygous UDP-GlcNAc 2-epimerase and N-acetylmannosamine kinase domain mutations in the GNE gene result in a less severe GNE myopathy phenotype compared to homozygous N-acetylmannosamine kinase domain mutations. Journal of the Neurological Sciences, 2012, 318, 100-105.	0.6	47
74	An autopsy case of a dysferlinopathy patient with cardiac involvement. Muscle and Nerve, 2012, 45, 298-299.	2.2	9
75	Increase in number of sporadic inclusion body myositis (sIBM) in Japan. Journal of Neurology, 2012, 259, 554-556.	3.6	49
76	Corticotropin-Releasing Hormone Receptor 1 Gene Variants in Irritable Bowel Syndrome. PLoS ONE, 2012, 7, e42450.	2.5	23
77	Herpes Labialis in Multiple Sclerosis with a Trigeminal Lesion. Internal Medicine, 2011, 50, 259-259.	0.7	4
78	A Case of Late Onset Riboflavin-responsive Multiple Acyl-CoA Dehydrogenase Deficiency Manifesting as Recurrent Rhabdomyolysis and Acute Renal Failure. Internal Medicine, 2011, 50, 2663-2668.	0.7	29
79	Feasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavenger. Brain Research, 2011, 1382, 321-325.	2.2	33
80	Optineurin is co-localized with FUS in basophilic inclusions of ALS with FUS mutation and in basophilic inclusion body disease. Acta Neuropathologica, 2011, 121, 555-557.	7.7	53
81	A Case of McArdle Disease: Efficacy of Vitamin B6 on Fatigability and Impaired Glycogenolysis. Internal Medicine, 2010, 49, 1623-1625.	0.7	14
82	Rapid Screening for Japanese Dysferlinopathy by Fluorescent Primer Extension. Internal Medicine, 2010, 49, 2693-2696.	0.7	8
83	Mutations of optineurin in amyotrophic lateral sclerosis. Nature, 2010, 465, 223-226.	27.8	1,097
84	Neuromyelitis optica preceded by hyperCKemia episode. Neurology, 2010, 74, 1543-1545.	1.1	62
85	Neuromyelitis optica preceded by hyperCKemia episode. Neurology, 2010, 75, 2253-2254.	1.1	8
86	FALS with FUS mutation in Japan, with early onset, rapid progress and basophilic inclusion. Journal of Human Genetics, 2010, 55, 252-254.	2.3	60
87	Neuronal NOS is dislocated during muscle atrophy in amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2010, 294, 95-101.	0.6	29
88	PROCALCITONIN MIGHT HELP IN DISCRIMINATION BETWEEN MENINGEAL NEURO-BEHÇET DISEASE AND BACTERIAL MENINGITIS. Neurology, 2009, 72, 762-763.	1.1	11
89	A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset. Neurology, 2009, 72, 1960-1961.	1.1	139
90	Dorsal-roots enhancement and Wallerian degeneration of dorsal cord in the patient of acute sensory ataxic neuropathy. Journal of Neurology, 2009, 256, 1765-1766.	3.6	3

#	ARTICLE	IF	CITATIONS
91	Intravenous Immunoglobulin Treatment Successfully Improved Subacute Progressive Polyradiculoneuropathy with Polyclonal Gammopathy. Internal Medicine, 2009, 48, 2037-2039.	0.7	0
92	Downstream utrophin enhancer is required for expression of utrophin in skeletal muscle. Journal of Gene Medicine, 2008, 10, 702-713.	2.8	10
93	Up-Regulation of Insulin-Like Growth Factor-II Receptor in Reactive Astrocytes in the Spinal Cord of Amyotrophic Lateral Sclerosis Transgenic Rats. Tohoku Journal of Experimental Medicine, 2008, 214, 303-310.	1.2	12
94	Gene therapy for Duchenne muscular dystrophy. Future Neurology, 2007, 2, 87-96.	0.5	2
95	Nitric oxide production results in disuse-induced muscle atrophy through dislocation of neuronal nitric oxide synthase. Neuroscience Research, 2007, 58, S177.	1.9	0
96	Distal anterior compartment myopathy with early ankle contractures. Muscle and Nerve, 2007, 36, 525-527.	2.2	17
97	NO production results in suspension-induced muscle atrophy through dislocation of neuronal NOS. Journal of Clinical Investigation, 2007, 117, 2468-2476.	8.2	157
98	Late-onset distal myopathy with rimmed vacuoles without mutation in the GNE or dysferlin genes. Muscle and Nerve, 2005, 32, 812-814.	2.2	5
99	Expression profiling with progression of dystrophic change in dysferlin-deficient mice (SJL). Neuroscience Research, 2005, 52, 47-60.	1.9	33
100	Novel dysferlin mutations and characteristic muscle atrophy in late-onset Miyoshi myopathy. Muscle and Nerve, 2004, 29, 721-723.	2.2	14